bridion174-sugammadex(已修改)
2024-10-16 09:05 本頁面
【正文】 Bridion174。 Sugammadex Manufacturer: Merck FDA Approval Date: December 15, 2020 Bridion174。 Sugammadex Objectives ? At the end of this presentation participants will be able to: 1. Appropriately remend Bridion174。 Sugammadex 2. Effectively educate patients on the purpose, proper use and potential adverse effects of Bridion174。 Sugammadex Bridion174。 Sugammadex Clinical Application ? Indications: ? Used for adults undergoing surgery for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium ? Not indicated to reverse blockade of nonsteroidal neuromuscular blocking agents (eg, succinylcholine) ? Not indicated for use in ICU setting Bridion174。 [package insert]. Bridion174。 Sugammadex Clinical Application ? Contraindications: ? Hypersensitivity to sugammadex or any ponent of the product ? Precautions: ? Use not remended with severe renal impairment or dialysisdependent patients ? Caution with mildtomoderate renal impairment (no dosage adjustment) Bridion174。 [package insert]. Bridion174。 Sugammadex Clinical Application ? Pregnancy: ? No available
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1